MEM Stock Overview
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Memphasys Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.009 |
| 52 Week High | AU$0.021 |
| 52 Week Low | AU$0.007 |
| Beta | 0.73 |
| 1 Month Change | -25.00% |
| 3 Month Change | -30.77% |
| 1 Year Change | -57.14% |
| 3 Year Change | -87.32% |
| 5 Year Change | -60.87% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Memphasys (ASX:MEM) Is Making Moderate Use Of Debt
Mar 01
Memphasys (ASX:MEM) Is Making Moderate Use Of Debt
Jun 13Does Memphasys (ASX:MEM) Have A Healthy Balance Sheet?
Jun 20Is Memphasys (ASX:MEM) A Risky Investment?
Feb 28Memphasys (ASX:MEM) Is Making Moderate Use Of Debt
Sep 01Will Memphasys (ASX:MEM) Spend Its Cash Wisely?
Jan 07Shareholder Returns
| MEM | AU Life Sciences | AU Market | |
|---|---|---|---|
| 7D | -10.0% | -4.1% | -2.8% |
| 1Y | -57.1% | -14.6% | 4.0% |
Return vs Industry: MEM underperformed the Australian Life Sciences industry which returned -14.6% over the past year.
Return vs Market: MEM underperformed the Australian Market which returned 4% over the past year.
Price Volatility
| MEM volatility | |
|---|---|
| MEM Average Weekly Movement | 19.5% |
| Life Sciences Industry Average Movement | 11.5% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.4% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: MEM's share price has been volatile over the past 3 months.
Volatility Over Time: MEM's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | David Ali | www.memphasys.com |
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix, a device separates sperm from raw semen by electrophoresis process for use in human IVF procedures. In addition, the company’s product pipeline include ROSA, a rapid oxidative stress assay; Samson Device, rapid equine pregnancy prediction assay; SemPort, a system that allows transport of semen; and AI-Port.
Memphasys Limited Fundamentals Summary
| MEM fundamental statistics | |
|---|---|
| Market cap | AU$12.31m |
| Earnings (TTM) | -AU$4.52m |
| Revenue (TTM) | AU$736.66k |
16.7x
P/S Ratio-2.7x
P/E RatioIs MEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEM income statement (TTM) | |
|---|---|
| Revenue | AU$736.66k |
| Cost of Revenue | AU$26.15k |
| Gross Profit | AU$710.50k |
| Other Expenses | AU$5.23m |
| Earnings | -AU$4.52m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0033 |
| Gross Margin | 96.45% |
| Net Profit Margin | -613.81% |
| Debt/Equity Ratio | 57.0% |
How did MEM perform over the long term?
See historical performance and comparison